Exact Sciences Corp.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Exact Sciences Corp.
The operating environment for medical technology companies becomes more complex, competitive and costly every year. There is no expectation that 2022 will buck that trend, even as the medtech sector prepares for a third year of working under conditions shaped by the COVID-19 pandemic.
IV BioHoldings CEO Marty Keiser connects data, technology, capital and people to create start-ups focusing on liquid biopsy programs.
Guardant Health Launches New Firsts: Blood Test To Track Patient’s Response To Immunotherapy, Tissue-Based Test
Guardant’s launch of a new test to track patient’s response to immunotherapy or targeted drugs and new pan-cancer tissue test, brings it closer to “one-stop-shop” in cancer care continuum.
John Leppard with Washington Analysis says the Medicare agency’s recent delay of the MCIT breakthrough devices rule until mid-December suggests the CMS will likely scrap it altogether and start from scratch.
- Laboratory Testing Services
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
- Base Genomics
- Genomic Health, Inc.
- Paradigm Diagnostics, Inc.
- Thrive Earlier Detection Corp.
- Viomics, Inc.